<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04218786</url>
  </required_header>
  <id_info>
    <org_study_id>STMU2020</org_study_id>
    <nct_id>NCT04218786</nct_id>
  </id_info>
  <brief_title>Effect of Colchicine in Patients With Myocardial Infarction</brief_title>
  <official_title>Outcomes of Low-dose Colchicine in Patients With Myocardial Infarction: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shifa Tameer-e-Millat University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rawalpindi Institute of Cardiology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shifa Tameer-e-Millat University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over the past years, a substantial volume of evidence has accumulated identifying
      inflammatory processes as key mediators of the deleterious effects of
      ischemia/reperfusion-related phenomena in patients presenting with ST-segment-elevation
      myocardial infarction (STEMI). Nevertheless, equally impressive is the lack of clinically
      applicable therapeutic strategies that could mitigate these processes, thus providing
      significant cardioprotection. Despite the well-known fact that inflammation plays an
      important role in coronary artery disease development and progression, there have been few
      attempts to systematically examine the potential role of anti-inflammatory treatment in this
      setting, possibly because of a lack in anti-inflammatory agents without the adverse
      cardiovascular safety profile of corticosteroids and nonsteroidal anti-inflammatory drugs.
      Colchicine is a substance with potent anti-inflammatory properties, having a unique mechanism
      of action, which allows for safe use in patients with cardiovascular disease.

      The purpose of the present clinical study is to test the hypothesis that a short course of
      treatment with colchicine could lead to reduced major adverse cardiovascular events (MACE) in
      acute MI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over the past years, a substantial volume of evidence has accumulated identifying
      inflammatory processes as key mediators of the deleterious effects of
      ischemia/reperfusion-related phenomena in patients presenting with ST-segment-elevation
      myocardial infarction (STEMI). Nevertheless, equally impressive is the lack of clinically
      applicable therapeutic strategies that could mitigate these processes, thus providing
      significant cardioprotection.

      Despite the well-known fact that inflammation plays an important role in coronary artery
      disease development and progression, there have been few attempts to systematically examine
      the potential role of anti-inflammatory treatment in this setting, possibly because of a lack
      in anti-inflammatory agents without the adverse cardiovascular safety profile of
      corticosteroids and nonsteroidal anti-inflammatory drugs. Some anti-inflammatory agents, like
      pexelizumab, are focused on complement cascade.Another agent is Varespladib, which targets
      sPLA2 that causes oxidative stress and inflammation. There are other therapeutic targets that
      have been widely investigated. Colchicine is a substance with potent anti-inflammatory
      properties, having a unique mechanism of action, which allows for safe use in patients with
      cardiovascular disease.

      Colchicine binds to non-polymerized tubulin, forming a stable complex that effectively
      inhibits the dynamic of microtubules, depolymerizing them. Thus, any process requiring
      changes in the cell cytoskeleton, such as cellular mitosis, exocytosis and neutrophil
      motility, is affected. Colchicine has an important effect on atrial myocytes, changing the
      atrial response to autonomic effects (reducing the sympathetic activity and increasing the
      parasympathetic one). Due to this particular mode of action, colchicine has been indicated in
      atrial fibrillation post-cardiac surgery. A similar trial is being conducted to investigate
      any effusions or syndromes that occur after myocardial infarction.

      The purpose of the present clinical study is to test the hypothesis that a short course of
      treatment with colchicine could lead to reduced major adverse cardiovascular events (MACE) in
      acute MI.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major cardiovascular adverse events (number of events)</measure>
    <time_frame>3 months</time_frame>
    <description>This outcome will be assessed using a questionnaire. The following headings will be used:
Cardiovascular death (number of events)
Non-fatal myocardial infarction (number of events)
Resuscitated cardiac arrest (number of events)
Hospitalization for unstable angina (number of events) For each heading, the total number of events will be recorded and the numbers will all be added to calculate 'Major Adverse Cardiovascular Events' in form of number of events. This outcome has no specific values of measure but a discrete numerical value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Troponin I (ng/ml)</measure>
    <time_frame>3 months</time_frame>
    <description>This workup will be recorded on the same questionnaire as a numerical value with its specific unit of measure upon followup of patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatine Kinase-Myocardial Band (IU/L)</measure>
    <time_frame>3 months</time_frame>
    <description>This workup will be recorded on the same questionnaire as a numerical value with its specific unit of measure upon followup of patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (mg/L)</measure>
    <time_frame>3 months</time_frame>
    <description>This workup will be recorded on the same questionnaire as a numerical value with its specific unit of measure upon followup of patient.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Myocardium; Injury</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Colchicine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive low dose colchicine, 0.5 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will receive a placebo drug with a similar shape and mass as that to experimental drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>The tablet will be given once daily for the span of the study</description>
    <arm_group_label>Colchicine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>The tablet will be given once daily for the span of the study</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients 18 years or above presenting in emergency department with acute
             myocardial infarction. These patients will be requested to take the medication at the
             time of discharge after stabilization and management

        Exclusion Criteria:

          -  Patients with prior myocardial infarction 30 days before

          -  Patients with ischemic cardiomyopathy

          -  Age &lt;18 or &gt; 80 years

          -  Active inflammatory or infectious disease or known malignancy

          -  Known hypersensitivity to colchicine,

          -  renal failure (eGFR &lt;30ml.min.1.73m)

          -  hepatic failure

          -  Stent thrombosis

          -  Cardiac arrest or cardiogenic shock as presenting symptoms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nismat Javed, MBBS student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shifa College of Medicine, Shifa Tameer-e-Millat University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jahanzeb Malik, MBBS (2011)</last_name>
    <role>Study Director</role>
    <affiliation>Rawalpindi Institute of Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adeel ur Rehman, MBBS, FCPS</last_name>
    <role>Study Chair</role>
    <affiliation>Rawalpindi Institute of Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rawalpindi Institute of Cardiology</name>
      <address>
        <city>Rawalpindi</city>
        <zip>46000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <reference>
    <citation>Turer AT, Hill JA. Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol. 2010 Aug 1;106(3):360-8. doi: 10.1016/j.amjcard.2010.03.032. Review.</citation>
    <PMID>20643246</PMID>
  </reference>
  <reference>
    <citation>Christia P, Frangogiannis NG. Targeting inflammatory pathways in myocardial infarction. Eur J Clin Invest. 2013 Sep;43(9):986-95. doi: 10.1111/eci.12118. Epub 2013 Jun 17. Review.</citation>
    <PMID>23772948</PMID>
  </reference>
  <reference>
    <citation>Adlbrecht C, Wurm R, Humenberger M, Andreas M, Redwan B, Distelmaier K, Klappacher G, Lang IM. Peri-interventional endothelin--a receptor blockade improves long-term outcome in patients with ST-elevation acute myocardial infarction. Thromb Haemost. 2014 Jul 3;112(1):176-82. doi: 10.1160/TH13-10-0832. Epub 2014 Apr 3.</citation>
    <PMID>24695986</PMID>
  </reference>
  <reference>
    <citation>He J, Li J, Wang Y, Hao P, Hua Q. Neutrophil-to-lymphocyte ratio (NLR) predicts mortality and adverse-outcomes after ST-segment elevation myocardial infarction in Chinese people. Int J Clin Exp Pathol. 2014 Jun 15;7(7):4045-56. eCollection 2014.</citation>
    <PMID>25120783</PMID>
  </reference>
  <reference>
    <citation>Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, Izawa A, Takahashi Y, Masumoto J, Koyama J, Hongo M, Noda T, Nakayama J, Sagara J, Taniguchi S, Ikeda U. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation. 2011 Feb 15;123(6):594-604. doi: 10.1161/CIRCULATIONAHA.110.982777. Epub 2011 Jan 31.</citation>
    <PMID>21282498</PMID>
  </reference>
  <reference>
    <citation>Chen K, Schenone AL, Borges N, Militello M, Menon V. Teaching an Old Dog New Tricks: Colchicine in Cardiovascular Medicine. Am J Cardiovasc Drugs. 2017 Oct;17(5):347-360. doi: 10.1007/s40256-017-0226-3. Review.</citation>
    <PMID>28353024</PMID>
  </reference>
  <reference>
    <citation>Robertson S, Martínez GJ, Payet CA, Barraclough JY, Celermajer DS, Bursill C, Patel S. Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation. Clin Sci (Lond). 2016 Jul 1;130(14):1237-46. doi: 10.1042/CS20160090. Epub 2016 Apr 21.</citation>
    <PMID>27129183</PMID>
  </reference>
  <reference>
    <citation>Misawa T, Takahama M, Kozaki T, Lee H, Zou J, Saitoh T, Akira S. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol. 2013 May;14(5):454-60. doi: 10.1038/ni.2550. Epub 2013 Mar 17.</citation>
    <PMID>23502856</PMID>
  </reference>
  <reference>
    <citation>Akodad M, Fauconnier J, Sicard P, Huet F, Blandel F, Bourret A, de Santa Barbara P, Aguilhon S, LeGall M, Hugon G, Lacampagne A, Roubille F. Interest of colchicine in the treatment of acute myocardial infarct responsible for heart failure in a mouse model. Int J Cardiol. 2017 Aug 1;240:347-353. doi: 10.1016/j.ijcard.2017.03.126. Epub 2017 Apr 1.</citation>
    <PMID>28395979</PMID>
  </reference>
  <reference>
    <citation>Rymer JA, Newby LK. Failure to Launch: Targeting Inflammation in Acute Coronary Syndromes. JACC Basic Transl Sci. 2017 Aug 28;2(4):484-497. doi: 10.1016/j.jacbts.2017.07.001. eCollection 2017 Aug. Review.</citation>
    <PMID>30062164</PMID>
  </reference>
  <reference>
    <citation>Pinckard RN, Olson MS, Giclas PC, Terry R, Boyer JT, O'Rourke RA. Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. J Clin Invest. 1975 Sep;56(3):740-50.</citation>
    <PMID>808560</PMID>
  </reference>
  <reference>
    <citation>Gora S, Maouche S, Atout R, Wanherdrick K, Lambeau G, Cambien F, Ninio E, Karabina SA. Phospholipolyzed LDL induces an inflammatory response in endothelial cells through endoplasmic reticulum stress signaling. FASEB J. 2010 Sep;24(9):3284-97. doi: 10.1096/fj.09-146852. Epub 2010 Apr 29.</citation>
    <PMID>20430794</PMID>
  </reference>
  <reference>
    <citation>Serruys PW, García-García HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Bøtker HE, von Birgelen C, D'Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A; Integrated Biomarker and Imaging Study-2 Investigators. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008 Sep 9;118(11):1172-82. doi: 10.1161/CIRCULATIONAHA.108.771899. Epub 2008 Sep 1.</citation>
    <PMID>18765397</PMID>
  </reference>
  <reference>
    <citation>Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011 Oct;162(4):597-605. doi: 10.1016/j.ahj.2011.06.012. Epub 2011 Sep 14.</citation>
    <PMID>21982649</PMID>
  </reference>
  <reference>
    <citation>Tanguay JF, Geoffroy P, Sirois MG, Libersan D, Kumar A, Schaub RG, Merhi Y. Prevention of in-stent restenosis via reduction of thrombo-inflammatory reactions with recombinant P-selectin glycoprotein ligand-1. Thromb Haemost. 2004 Jun;91(6):1186-93.</citation>
    <PMID>15175806</PMID>
  </reference>
  <reference>
    <citation>Surinkaew S, Kumphune S, Chattipakorn S, Chattipakorn N. Inhibition of p38 MAPK during ischemia, but not reperfusion, effectively attenuates fatal arrhythmia in ischemia/reperfusion heart. J Cardiovasc Pharmacol. 2013 Feb;61(2):133-41. doi: 10.1097/FJC.0b013e318279b7b1.</citation>
    <PMID>23107875</PMID>
  </reference>
  <reference>
    <citation>Fujisue K, Sugamura K, Kurokawa H, Matsubara J, Ishii M, Izumiya Y, Kaikita K, Sugiyama S. Colchicine Improves Survival, Left Ventricular Remodeling, and Chronic Cardiac Function After Acute Myocardial Infarction. Circ J. 2017 Jul 25;81(8):1174-1182. doi: 10.1253/circj.CJ-16-0949. Epub 2017 Apr 18.</citation>
    <PMID>28420825</PMID>
  </reference>
  <reference>
    <citation>Martínez GJ, Robertson S, Barraclough J, Xia Q, Mallat Z, Bursill C, Celermajer DS, Patel S. Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome. J Am Heart Assoc. 2015 Aug 24;4(8):e002128. doi: 10.1161/JAHA.115.002128.</citation>
    <PMID>26304941</PMID>
  </reference>
  <reference>
    <citation>Deftereos S, Giannopoulos G, Angelidis C, Alexopoulos N, Filippatos G, Papoutsidakis N, Sianos G, Goudevenos J, Alexopoulos D, Pyrgakis V, Cleman MW, Manolis AS, Tousoulis D, Lekakis J. Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study. Circulation. 2015 Oct 13;132(15):1395-403. doi: 10.1161/CIRCULATIONAHA.115.017611. Epub 2015 Aug 11.</citation>
    <PMID>26265659</PMID>
  </reference>
  <reference>
    <citation>Singhal R, Chang SL, Chong E, Hsiao YW, Liu SH, Tsai YN, Hsu CP, Lin YJ, Lo LW, Ha TL, Chen YC, Chen YJ, Chiou CW, Chen SA. Colchicine suppresses atrial fibrillation in failing heart. Int J Cardiol. 2014 Oct 20;176(3):651-60. doi: 10.1016/j.ijcard.2014.07.069. Epub 2014 Aug 17.</citation>
    <PMID>25164186</PMID>
  </reference>
  <reference>
    <citation>Imazio M, Brucato A, Cemin R, Ferrua S, Maggiolini S, Beqaraj F, Demarie D, Forno D, Ferro S, Maestroni S, Belli R, Trinchero R, Spodick DH, Adler Y; ICAP Investigators. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013 Oct 17;369(16):1522-8. doi: 10.1056/NEJMoa1208536. Epub 2013 Aug 31.</citation>
    <PMID>23992557</PMID>
  </reference>
  <reference>
    <citation>Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, López-Sendón J, Ostadal P, Koenig W, Angoulvant D, Grégoire JC, Lavoie MA, Dubé MP, Rhainds D, Provencher M, Blondeau L, Orfanos A, L'Allier PL, Guertin MC, Roubille F. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019 Dec 26;381(26):2497-2505. doi: 10.1056/NEJMoa1912388. Epub 2019 Nov 16.</citation>
    <PMID>31733140</PMID>
  </reference>
  <reference>
    <citation>Deftereos S, Giannopoulos G, Papoutsidakis N, Panagopoulou V, Kossyvakis C, Raisakis K, Cleman MW, Stefanadis C. Colchicine and the heart: pushing the envelope. J Am Coll Cardiol. 2013 Nov 12;62(20):1817-25. doi: 10.1016/j.jacc.2013.08.726. Epub 2013 Sep 11. Review.</citation>
    <PMID>24036026</PMID>
  </reference>
  <reference>
    <citation>Head BP, Patel HH, Roth DM, Murray F, Swaney JS, Niesman IR, Farquhar MG, Insel PA. Microtubules and actin microfilaments regulate lipid raft/caveolae localization of adenylyl cyclase signaling components. J Biol Chem. 2006 Sep 8;281(36):26391-9. Epub 2006 Jul 3.</citation>
    <PMID>16818493</PMID>
  </reference>
  <reference>
    <citation>Malan D, Gallo MP, Bedendi I, Biasin C, Levi RC, Alloatti G. Microtubules mobility affects the modulation of L-type I(Ca) by muscarinic and beta-adrenergic agonists in guinea-pig cardiac myocytes. J Mol Cell Cardiol. 2003 Feb;35(2):195-206.</citation>
    <PMID>12606260</PMID>
  </reference>
  <reference>
    <citation>Imazio M, Brucato A, Ferrazzi P, Rovere ME, Gandino A, Cemin R, Ferrua S, Belli R, Maestroni S, Simon C, Zingarelli E, Barosi A, Sansone F, Patrini D, Vitali E, Trinchero R, Spodick DH, Adler Y; COPPS Investigators. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation. 2011 Nov 22;124(21):2290-5. doi: 10.1161/CIRCULATIONAHA.111.026153. Epub 2011 Nov 16.</citation>
    <PMID>22090167</PMID>
  </reference>
  <reference>
    <citation>Zarpelon CS, Netto MC, Jorge JC, Fabris CC, Desengrini D, Jardim Mda S, Silva DG. Colchicine to Reduce Atrial Fibrillation in the Postoperative Period of Myocardial Revascularization. Arq Bras Cardiol. 2016 Jul;107(1):4-9. doi: 10.5935/abc.20160082. Epub 2016 May 24. English, Portuguese.</citation>
    <PMID>27223641</PMID>
  </reference>
  <reference>
    <citation>Imazio M, Belli R, Brucato A, Ferrazzi P, Patrini D, Martinelli L, Polizzi V, Cemin R, Leggieri A, Caforio AL, Finkelstein Y, Hoit B, Maisch B, Mayosi BM, Oh JK, Ristic AD, Seferovic P, Spodick DH, Adler Y. Rationale and design of the COlchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative Atrial Fibrillation (COPPS-2 trial): a randomized, placebo-controlled, multicenter study on the use of colchicine for the primary prevention of the postpericardiotomy syndrome, postoperative effusions, and postoperative atrial fibrillation. Am Heart J. 2013 Jul;166(1):13-9. doi: 10.1016/j.ahj.2013.03.025. Epub 2013 May 6. Review.</citation>
    <PMID>23816016</PMID>
  </reference>
  <reference>
    <citation>Imazio M, Bobbio M, Cecchi E, Demarie D, Demichelis B, Pomari F, Moratti M, Gaschino G, Giammaria M, Ghisio A, Belli R, Trinchero R. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005 Sep 27;112(13):2012-6.</citation>
    <PMID>16186437</PMID>
  </reference>
  <reference>
    <citation>Imazio M, Bobbio M, Cecchi E, Demarie D, Pomari F, Moratti M, Ghisio A, Belli R, Trinchero R. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med. 2005 Sep 26;165(17):1987-91.</citation>
    <PMID>16186468</PMID>
  </reference>
  <reference>
    <citation>Imazio M, Brucato A, Cemin R, Ferrua S, Belli R, Maestroni S, Trinchero R, Spodick DH, Adler Y; CORP (COlchicine for Recurrent Pericarditis) Investigators. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011 Oct 4;155(7):409-14. doi: 10.7326/0003-4819-155-7-201110040-00359. Epub 2011 Aug 28.</citation>
    <PMID>21873705</PMID>
  </reference>
  <reference>
    <citation>Imazio M, Belli R, Brucato A, Cemin R, Ferrua S, Beqaraj F, Demarie D, Ferro S, Forno D, Maestroni S, Cumetti D, Varbella F, Trinchero R, Spodick DH, Adler Y. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014 Jun 28;383(9936):2232-7. doi: 10.1016/S0140-6736(13)62709-9. Epub 2014 Mar 30.</citation>
    <PMID>24694983</PMID>
  </reference>
  <reference>
    <citation>Verma S, Eikelboom JW, Nidorf SM, Al-Omran M, Gupta N, Teoh H, Friedrich JO. Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2015 Aug 29;15:96. doi: 10.1186/s12872-015-0068-3. Review.</citation>
    <PMID>26318871</PMID>
  </reference>
  <reference>
    <citation>Leung YY, Yao Hui LL, Kraus VB. Colchicine--Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015 Dec;45(3):341-50. doi: 10.1016/j.semarthrit.2015.06.013. Epub 2015 Jun 26. Review.</citation>
    <PMID>26228647</PMID>
  </reference>
  <reference>
    <citation>Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011 Aug;63(8):2226-37. doi: 10.1002/art.30389. Erratum in: Arthritis Rheum. 2011 Nov;63(11):3521. Dosage error in article text.</citation>
    <PMID>21480191</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 1, 2020</study_first_submitted>
  <study_first_submitted_qc>January 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2020</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shifa Tameer-e-Millat University</investigator_affiliation>
    <investigator_full_name>Nismat Javed</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>colchicine; outcome: myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

